Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : Mtnb exchanges : Amex save search
Matinas BioPharma Prices $10 Million Registered Direct Offering
Published: 2024-04-03 (Crawled : 12:30) - globenewswire.com
MTNB | $0.18 -4.1% 1.0% 1.4M
|
Health Technology
|
| O: -20.29%
H: 0.0%
C: -18.46%
million direct offering biopharma
Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update
Published: 2024-03-27 (Crawled : 20:00) - globenewswire.com
BNTX | News | $88.01 1.38% 1.36% 340K
|
Health Technology
|
| O: -0.08%
H: 1.01%
C: -0.7%
MTNB | $0.18 -4.1% 1.0% 1.4M
|
Health Technology
|
| O: -3.38%
H: 2.32%
C: -3.25%
business update biopharma financial results
Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation
Published: 2024-03-25 (Crawled : 12:00) - globenewswire.com
MTNB | $0.18 -4.1% 1.0% 1.4M
|
Health Technology
|
| O: 15.11%
H: 0.0%
C: -9.31%
positive biopharma
Three Patients with Invasive Fusarium Infection in Matinas BioPharma’s Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical Response
Published: 2024-03-22 (Crawled : 13:00) - globenewswire.com
MTNB | $0.18 -4.1% 1.0% 1.4M
|
Health Technology
|
| O: 8.94%
H: 48.28%
C: -4.14%
mat2203 infection program response
Matinas BioPharma Regains Compliance with NYSE American Continued Listing Standards
Published: 2024-03-22 (Crawled : 11:00) - globenewswire.com
MTNB | $0.18 -4.1% 1.0% 1.4M
|
Health Technology
|
| O: 8.94%
H: 48.28%
C: -4.14%
biopharma
Matinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolution
Published: 2024-02-26 (Crawled : 13:00) - globenewswire.com
MTNB | $0.18 -4.1% 1.0% 1.4M
|
Health Technology
|
| O: 1.59%
H: 15.13%
C: 10.61%
mat2203 positive update biopharma
Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis
Published: 2024-02-20 (Crawled : 12:30) - globenewswire.com
MTNB | $0.18 -4.1% 1.0% 1.4M
|
Health Technology
|
| O: 4.35%
H: 11.21%
C: -0.46%
mat2203 fda treatment biopharma trial agreement
Matinas BioPharma to Present at Biotech Showcase 2024
Published: 2024-01-03 (Crawled : 12:00) - globenewswire.com
MTNB | $0.18 -4.1% 1.0% 1.4M
|
Health Technology
|
| O: -2.04%
H: 2.54%
C: 0.05%
biotech biopharma
Matinas BioPharma Demonstrates in vivo Biological Activity and Disease Improvement in Two Inflammatory Disease Models with Oral LNC-Delivered Small Oligonucleotides
Published: 2023-12-27 (Crawled : 12:30) - globenewswire.com
MTNB | $0.18 -4.1% 1.0% 1.4M
|
Health Technology
|
| O: 11.99%
H: 14.6%
C: 7.52%
disease biopharma
Matinas BioPharma Provides Update to MAT2203 Regulatory and Development Pathway Following Feedback from FDA
Published: 2023-12-21 (Crawled : 12:30) - globenewswire.com
MTNB | $0.18 -4.1% 1.0% 1.4M
|
Health Technology
|
| O: 2.27%
H: 0.0%
C: -3.82%
mat2203 fda update biopharma
Matinas BioPharma Announces Positive in vivo Efficacy Results of Oral LNC Docetaxel Formulation in a Melanoma Model
Published: 2023-11-07 (Crawled : 13:00) - globenewswire.com
MTNB | $0.18 -4.1% 1.0% 1.4M
|
Health Technology
|
| O: 21.22%
H: 4.92%
C: 4.92%
melanoma positive biopharma results
Matinas BioPharma to Webcast Conference Call to Discuss Third Quarter 2023 Financial Results and Provide a Business Update on November 8, 2023
Published: 2023-11-01 (Crawled : 11:00) - globenewswire.com
MTNB | $0.18 -4.1% 1.0% 1.4M
|
Health Technology
|
| O: -3.01%
H: 8.04%
C: -1.88%
conference business update biopharma financial results
Patient with Candida krusei Infection in Matinas BioPharma’s Oral MAT2203 Expanded Access Program Achieves Complete Clinical Resolution
Published: 2023-10-11 (Crawled : 12:00) - globenewswire.com
MTNB | $0.18 -4.1% 1.0% 1.4M
|
Health Technology
|
| O: 74.26%
H: 229.51%
C: 137.32%
mat2203 infection program
Matinas BioPharma to Present at Two Investment Conferences in October 2023
Published: 2023-09-28 (Crawled : 11:00) - globenewswire.com
MTNB | $0.18 -4.1% 1.0% 1.4M
|
Health Technology
|
| O: 2.51%
H: 0.0%
C: -3.7%
biopharma
Matinas BioPharma to Feature MAT2203 in a Pipeline Presentation at IDWeek
Published: 2023-09-27 (Crawled : 11:00) - globenewswire.com
MTNB | $0.18 -4.1% 1.0% 1.4M
|
Health Technology
|
| O: -0.71%
H: 5.57%
C: -5.93%
mat2203 presentation pipeline biopharma
Matinas BioPharma Announces Notification of NYSE American Continued Listing Deficiency
Published: 2023-09-22 (Crawled : 21:00) - globenewswire.com
MTNB | $0.18 -4.1% 1.0% 1.4M
|
Health Technology
| Email alert
Add to watchlist
biopharma
Matinas BioPharma to Participate in the H.C. Wainwright Global Investment Conference
Published: 2023-09-06 (Crawled : 11:00) - globenewswire.com
MTNB | $0.18 -4.1% 1.0% 1.4M
|
Health Technology
|
| O: 4.5%
H: 0.0%
C: -9.4%
conference biopharma global
Matinas BioPharma Announces Publication of Results from the Phase 2 EnACT Clinical Trial of MAT2203 in the IDSA Journal Clinical Infectious Diseases
Published: 2023-08-22 (Crawled : 12:00) - globenewswire.com
MTNB | $0.18 -4.1% 1.0% 1.4M
|
Health Technology
|
| O: 21.95%
H: 0.0%
C: -19.9%
mat2203 publication biopharma trial results
Matinas BioPharma to Participate in the BTIG Virtual Biotechnology Conference 2023
Published: 2023-08-02 (Crawled : 11:00) - globenewswire.com
MTNB | $0.18 -4.1% 1.0% 1.4M
|
Health Technology
|
| O: -1.33%
H: 4.29%
C: -2.57%
conference biopharma
Matinas BioPharma to Webcast Conference Call to Discuss Second Quarter 2023 Financial Results and Provide a Business Update on August 9, 2023
Published: 2023-07-26 (Crawled : 12:00) - globenewswire.com
MTNB | $0.18 -4.1% 1.0% 1.4M
|
Health Technology
|
| O: 0.0%
H: 5.0%
C: 2.5%
conference business update biopharma financial results
Gainers vs Losers
| 74% | 26% |
Top 10 Gainers
MTTR | News M | $4.8 175.86% 63.6% 71M
|
AGBA | $2.5 100.0% 56.6% 200M
|
Finance
MLEC | $2.47 76.43% 42.62% 78M
|
n/a
NUWE | $0.334 29.96% 40.99% 2.5M
|
Manufacturing
EDBL | News | $6.26 66.49% 40.13% 16M
|
ATGL | $2.86 46.25% 32.8% 180K
|
VIVK | $1.43 33.65% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.7M
|
SDIG A | $3.64 35.32% 26.0% 990K
|
PROK | $2.72 33.33% 24.58% 2.6M
|
Your saved searches
Save your searches and get alerts when important news are released.